Graefes Arch Clin Exp Ophthalmol
November 2007
Aim: To determine the anatomical and functional outcome after injection of bevacizumab (Avastin, Genentech) in eyes with retinal angiomatous proliferation (RAP).
Design: Prospective interventional case series.
Methods: Sixteen eyes of 16 consecutive patients with visual loss due to RAP underwent intravitreal injections of 1.